Sandoz prepares early 2019 launch for EpiPen alternative Symjepi at 16% discount

Novartis' Sandoz unit licensed U.S. rights to Adamis' Symjepi in July. (Novartis)

Only days after Teva launched its generic to Mylan’s EpiPen, Novartis’ Sandoz has released launch plans for its own epinephrine injector product. Sandoz’s Symjepi won FDA approval in September, and on Thursday the company said it will launch in early 2019 at a slight discount to options from Mylan and Teva. 

While Teva opted not to release its medication with a list-price discount compared with Mylan’s authorized generic, Sandoz is going with a 16% discount.

Sandoz’s two-pack will hit the market with a list price of $250, while Teva and Mylan injectors cost $300 for a two-pack.

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

Sandoz is “well underway to ensure appropriate supply of this life-saving medicine for healthcare professionals and patients in need of a new treatment option,” according to a Thursday release

RELATED: Look out, EpiPen. With Adamis deal, Novartis is gunning for your sales 

Adamis Pharmaceuticals developed Symjepi and licensed U.S. rights to the epinephrine injector to Sandoz in July. The product won FDA approval in September. 

Thursday's news follows Teva’s generic EpiPen launch late last month. That drugmaker suffered two years of regulatory delays and finally won approval in August. 

Earlier in the EpiPen saga, Mylan faced criticism for routine price hikes that took branded EpiPen’s price to more than $600 for a two-pack. Amid the controversy, the company said it would release an authorized generic, which now costs $300 for a two-pack.

Due to new competition and new scrutiny on its big-selling injector, EpiPen sales fell $655 million last year, Mylan disclosed.

Suggested Articles

Pfizer has scored FDA approval for its Humira biosimilar, but it can't launch the product for several years under a patent settlement.

The 3-2 vote on the deal was split along the party lines, spelling trouble for future biopharma M&A deals should Democrats move into the White House.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.